Abstract
Introduction
Human carboxylesterases are members of serine esterases, metabolize ester, thioester, carbamate, and amide and yield soluble acids and alcohols or amines (Saitoh and Hosokawa, 1998; Satoh et al., 2002) . Two major isoforms of human carboxylesterase, hCE-1 and hCE-2, have been identified in the liver (Shibata et al., 1993; Schwer et al., 1997) . The CES2 gene encoding hCE-2 is located on chromosome 16q22.1 and consists of 12 exons (Fig. 1 ). hCE-2 has been shown to be expressed in relatively limited tissues, including the small intestine, colon, heart, kidney, and liver, while hCE-1 is ubiquitously distributed (Satoh et al., 2002; Xie et al., 2002) . hCE-2 is relatively specific for heroin, cocain (benzoyl ester), 6-acetylmorphine, procaine, and oxybutynin, although both isoforms show broad substrate specificities (Satoh et al., 2002; Pindel et al., 1997; Takai et al., 1997) . hCE-2 has also been shown to catalyze the conversion of the anti-tumor drug, irinotecan, into its active metabolite SN-38
(7-ethyl-10-hydroxy-camptothecin) (Takai et al., 1997; Humerickhouse et al., 2000) .
Data on the hepatic hydrolyzing activities of hCE-2 toward irinotecan revealed remarkable inter-individual difference (Xu et al., 2002) . With regard to genetic polymorphisms including single nucleotide polymorphisms (SNPs) in the CES2 gene, it has recently been shown that the allele and haplotype frequencies are significantly different between Europeans and Africans (Marsh et al, 2004) . In our previous study, we found a number of SNPs, including a nonsynonymous SNP (100C>T causing R34W, MPJ6_CS2005) and an SNP at the splice acceptor site of intron 8 (IVS8-2A>G, MPJ6_CS2011) in the course of screening CES2 SNPs from 153 Japanese individuals, who were administered irinotecan or beclomethasone (Kim et al., 2003) . Additional nonsynonymous SNPs (424G>A, V142M, MPJ6-CS2015) have been discovered in
further screening of CES2 SNPs in Japanese allergic patients (Fig. 1 ).
As the large ethnic differences of the CES2 SNP frequencies pointed out by Marsh et al.
( Marsh et al., 2004) , the SNPs we found have not been elaborated in the Marsh's literature, suggesting that the ones found by us were less frequent in Europeans and Africans.
In the present study, we performed functional characterization of the two nonsynonymous SNPs using heterologous cell expression systems. To investigate the effect of SNP IVS8-2A>G on RNA splicing, a minigene assay was adopted. The results indicated that the 2 hCE-2 variants (R34W and V142M) almost completely lost the enzymatic activities toward irinotecan and 2 typical carboxylesterase substrates, p-nitrophenol acetate and 4-methylumbelliferyl acetate. The exon-intron junction SNP, IVS8-2A>G, was associated with aberrant splicing.
Materials and Methods
SNP detection
SNPs in the CES2 gene (NT_010498.15 as a reference sequence) were surveyed by sequencing performed as described previously (Kim et al., 2003) . In the present study, 81 Japanese cancer patients administered irinotecan, 72 Japanese asthmatic patients administered beclomethasone, and 12 Japanese allergic patients administered steroidal drugs, whose genomic DNAs were extracted from blood leukocytes, were analyzed for CES2 SNPs. Each of the three SNPs elaborated in the present study was found separately as heterozygotes among the 165 subjects studied. The ethics committees of the National Cancer Center, National Center for Child Health and Development, and National Institute of Health Sciences approved this study. Written informed consent was obtained from all patients.
Construction of plasmids for a COS-1 cell expression system
Wild-type CES2 cDNA was obtained by the PCR amplification of a first strand cDNA synthesized by a reverse transcriptase (RT) reaction from Human Liver PolyA+ RNA (Clontech, Palo Alto, CA) using CES2 specific primers (5'CTGGATCCGACCATGCGGCTGCACAG3' and 5'ACAGGGAGCTACAGCTCTGTGT3', forward and reverse primers, respectively).
The PCR was performed with 1.25 units of AmpliTaq Gold (Applied Biosystems) for 95 ° C for 10 min, followed by 30 cycles of 95
a template for the preparation of R34W and V142M plasmids. The variant plasmids were generated with a QuickChange PCR site-directed mutagenesis kit (Stratagene, La.
Jolla, CA). The primers for the respective variations were 5'TCAGCCAGTCCCATCTGGACCACACACACGG3' for R34W and 5'GATCCACACCATCATCGGCAGGTTAGAGCC3' for V142M (mutated sites are underlined). The sequence of each variant cDNA was confirmed.
Construction of plasmids for a His-tagged hCE-2 expression
A histidine (His)-tagged hCE-2 expression plasmid was also constructed to obtain the KpnI. This newly generated plasmid was designated pHisCES2.
Construction of plasmids for the minigene assay
To construct plasmids for the minigene assay, a wild-type CES2 gene fragment was amplified by PCR using genomic DNA as a template that was extracted from an irinotecan-administered cancer patient with the wild-type or variant (IVS8-2A>G) CES2
genes. PCR primers used to amplify a CES2 gene fragment containing exons 7 to 10
were 5'GCACGCGTGGAGTGGTGGATGGGGTCTTC3' (forward primer, MluI site is underlined) and 5'GCGTCGACGGCTGATGCTGGAACTCGTAGA3' (reverse primer,.8
SalI site is underlined). The amplified fragments were cloned into a pCR3.1 vector.
After confirmation of the correct sequence, the CES2 fragment was digested with MluI and SalI and ligated into pCMV-TnT (Invitrogen) that had been digested with MluI and SalI. The plasmids containing the wild-type and IVS8-2G CES2 fragments were designated pCMV-CES2WT and pCMV-CES2IVS8G, respectively. The sequence of the inserts was confirmed.
Protein and mRNA expressions of wild-type and variant hCE-2s in COS-1 cells
COS-1 cells were seeded in 100-mm culture dishes. The cells were grown to reach approximately 70% confluency and rinsed with serum-free OPTI-MEM (Invitrogen) before transfection. The pCR3.1, pCR3.1/CES2 Wild-type, pCR3.1/CES2 R34W, and pCR3.1/CES2 V142M plasmids (6 µg each) were transfected individually using the LipofectAMINE PLUS reagent (Invitrogen) as described previously (Murayama et al., 2004) . The cells were harvested after 48 h and homogenized in 100 mM potassium phosphate buffer (pH 7.4). Cell homogenates were spun at 9000 x g for 10 min, and the resultant supernatants were then subjected to centrifugation at 105,000 x g for 1 h. The pellets were resuspended in a 250 mM sucrose solution and used as microsomes.
mRNA expressions of the wild-type and variant (R34W and V142M) hCE-2 cDNA-transfected cells were determined by a reverse-transcription PCR method.
(Invitrogen). Four hours after IPTG induction, the bacterial cells were harvested.
The ProBond Purification System (Invitrogen) was used to purify His-tagged hCE-2.9
expressed in TOP10 cells. The purification was performed with a denaturing condition according to the manufacturer's protocol. The purified protein was kept at -80 ° C in 2% SDS and used as a standard in Western blotting. Protein concentration of the purified His-tagged hCE-2 was quantified colorimetrically using the Protein Assay (Bio-Rad, Hercules, CA) and an hCE-2-specific band was confirmed by Western blotting.
Western blot analysis
Two or four μ g of the microsomes from COS-1 cells were resolved by 7.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Immunochemical detection of each hCE-2 protein was performed using rabbit anti-human hCE-2 raised against a peptide antigen (residues 539-555, KKALPQKIQELEEPEER) (diluted 1:2000). To verify that the samples were evenly loaded, the blot was subsequently treated with stripping buffer and reprobed with a polyclonal anti-calnexin antibody (diluted 1:4000; Stressgen Biotechnologies Inc., San Diego, CA). Visualization of these proteins was achieved with horseradish peroxidase-conjugated donkey anti-rabbit Ig (1:2000) and Enhanced
Chemiluminescence-Plus reagents (Amersham Biosciences Inc., Piscataway, NJ). The densities of protein bands were quantified using His-tagged hCE-2 as a standard. Two, four, and eight ng of the His-tagged hCE-2 were applied on the polyacrylamide gels for
Western blotting. The amounts of wild-type and the variants were within the range (2-8 ng) of the standard His-tagged hCE-2. Minigene assay.
HepG2 cells were rinsed with serum-free OPTI-MEM (Invitrogen) before transfection. Either pCMV-CES2WT or pCMV-CES2IVS8G was added to the cells with LipofectAMINE PLUS reagent (Invitrogen). The cells were harvested after 48 h, and total RNA was extracted with an RNeasy Mini Kit (Qiagen, Hilden, Germany).
RT-PCR was performed with a GeneAmp RNA PCR Kit (Applied Biosystems, Foster City, CA) using total RNA treated with DNaseI Amplification Grade (Invitrogen) as a template, an intron-skipping primer as a forward primer and a reverse primer having a portion of the exon 10 sequence (Fig. 4A) . The intron-skipping primer (5'GAGGCACTGGGCAGGTGTCCACTC3') was designed to cover both the artificial introns of pCMVTnT. RT-PCR products were detected by 3% agarose gel electrophoresis.
To analyze transcripts obtained by the minigene assay, the resultant RT-PCR products were cloned into pCR4-TOPO with the TOPO TA Cloning Kit for Sequencing (Invitrogen), and subsequent sequencing of the inserts derived from randomly isolated clones (greater than 100) was performed using an M13 reverse primer.
the wild-type. 
In vitro splicing assay of IVS8-2A>G
A minigene assay was performed with plasmids containing partial genomic sequences from exon 7 to exon 10 including the IVS8A>G SNP (Fig. 4A) . The RT-PCR products were analyzed by electrophoresis in a high-resolving agarose gel (Fig. 4B ). In the wild-type CES2-transfected HepG2 cells, a normally spliced mRNA was detected as a major product.
In contrast, mRNA from the variant plasmid-transfected HepG2 cells revealed that a number of abnormally spliced mRNAs were generated. Sequences of the aberrant transcripts ( Fig. 4A and 4B , products a-c) were directly determined. The main transcripts found with the variant minigene were product c with an exon 9 skipping and product b with a 32-bp deletion proximal to the 5'-end of exon 9 (Fig. 4C, b) . These splicing aberrations result in frameshifts and truncations of hCE-2. The sequence electropherogram for product b showed the presence of other minor transcripts.
To analyze the abnormal transcripts in detail, the RT-PCR products were cloned into a TA cloning vector. Subsequently, the cDNA sequences were determined for more than 
Discussion
The main point of this study is to functionally characterize three hCE-2 SNPs that we found among 165 Japanese subjects. Our functional characterization of the two nonsynonymous SNPs (R34W and V142M) revealed that the variants had an inefficient property as carboxylesterases at least toward irinotecan, p-nitrophenyl acetate and 4-methylumbelliferyl acetate (Table 1) . Expression levels of R34W and V142M variants were higher than the wild-type (252% and 360% of wild-type levels, respectively). We measured mRNA levels for the wild-type and the variant hCE-2 cDNA-transfected cells. The three amino acid residues, Ser-228, Glu-345, and His-457, in hCE-2 are highly conserved in carboxyesterase family proteins and are an active center of the enzyme.
Moreover, most of the CES family proteins have a C-terminal HXEL tetrapeptide that is required for their ER retention. As compared to the wild-type hCE-2 (559 amino acids), the 32-bp deleted variant yields a protein of 508 amino acids that lacks His457 in the active center and the C-terminal HXEL sequence. Thus, our findings obtained by the in vitro splicing assay suggest that the variant IVS8-2A>G might be a loss-of-function allele.
The SNPs, R34W and IVS8-2A>G, were found in irinotecan-administered Japanese cancer patients. The plasma concentrations of irinotecan, SN-38, and its glucuronide conjugate SN-38G were measured up to 24 h after a 90 min-infusion of irinotecan. The metabolite/parent ratio of their area under plasma concentration curves (AUC) {i.e., the ratio of the areas under the plasma concentration curves of SN-38 plus SN-38G to irinotecan: (AUC SN-38 +AUC SN-38G )/AUC irinotecan } could be considered as an estimate of the hepatic carboxylesterase activity. The heterozygous R34W patient, who suffered from colon cancer and was administered irinotecan, showed a low AUC ratio (unpublished data). On
the other hand, the AUC ratio of the IVS8-2A>G patient that suffered from small cell lung cancer and was administered irinotecan was a little higher than the median value. Since the patient had a homozygous variant ABCG2 (Glu141Lys), which was shown to be associated with the increase in AUC of diflomotecan, another topoisomerase I inhibitor (Sparreboom et al., 2004) , bile excretion of SN-38 and SN-38G was presumably lower by the ABCG2 variation, and as a result, plasma concentrations of SN-38 and SN-38G might have a tendency to increase (unpublished data).
Thus, the clinical impact of IVS8-2A>G is unclear. All these CES2 SNPs might be important for disease susceptibility as well, although it seems difficult to correlate certain diseases with SNPs with very low frequencies.
In conjunction with the large substrate-dependent inter-individual variability, it could be very valuable knowledge if our analyzing 3 SNPs were associated with the large inter-individual difference, as the difference is known to be as high as 5-to 45-fold (Hosokawa et al., 1995) or even 3-to 5-fold variability in irinotecan and p-nitrophenyl acetate, and butyrylthiocholine plasma hydrolytic activity (Guemei et al., 2001) . However, considering the low SNP frequencies (0.003) and the low activities of the variants observed throughout irinotecan and the 2 typical carboxylesterase substrates, contribution of our SNPs to the observed wide substrate-dependent inter-individual difference is less likely.
In conclusion, two nonsynonymous SNPs (causing R34W and V142M) were identified as deficient alleles. An in vitro splicing assay also suggested that IVS8-2A>G might be a low-activity allele although studies on more patients with the IVS8-2A>G are necessary in order to obtain conclusive data. The information on the remarkable functional changes in vitro caused by the three CES2 SNPs would be useful for the modification of dosage regimens in irinotecan therapy. Microsomes from the cDNA transfected cells were subjected to SDS-polyacrylamide gel electrophoresis together with human liver microsomes (2 µg) and His-tagged hCE-2 (6 ng) as a standard. Detection was performed with a rabbit anti-human hCE-2 antiserum (upper) and anti-human calnexin antiserum (lower) as described in Materials and Methods. A representative result of three independent experiments is shown.
Expression levels of R34W and V142M variants were higher than the wild-type (252% and 360% of wild-type levels, respectively). 
